We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensing Platform Diagnoses Diseases Through Single Molecule Detection

By LabMedica International staff writers
Posted on 15 Sep 2020
A new diagnostic approach employs a DNA origami biosensor platform coupled with a nanopore read-out that enables individual biomarker detection.

The ability to detect low concentrations of biomarkers in patient samples is one of the cornerstones of modern healthcare. More...
In general, biosensing approaches are based on measuring signals resulting from the interaction of a large ensemble of molecules with the sensor. To increase the sensitivity of this approach, investigators at the University of Leeds (United Kingdom) developed a biosensor platform using DNA origami, which featured a central cavity with a target-specific DNA aptamer coupled with a nanopore read-out to enable individual biomarker detection.

DNA origami is the nanoscale folding of DNA to create non-arbitrary two- and three-dimensional nanoscale shapes. The current method of DNA origami involves the folding of a long single strand of viral DNA aided by multiple smaller "staple" strands. These shorter strands bind the longer in various places, resulting in the formation of a pre-defined two- or three-dimensional shape.

Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, nucleic acids, and even cells, tissues, and organisms. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications.

The University of Leeds investigators demonstrated that DNA aptamer-functionalized DNA origami could capture an analyte of interest, and that the occupied and unoccupied DNA origami’s translocation fingerprints were readily distinguishable. In this study, they revealed a biosensing platform with a three nanomolar limit of detection, which was capable of detecting human C-reactive protein (CRP) in clinically relevant fluids.

The investigators reported that in addition to the characteristically different peak shape, also the peak amplitude, and dwell time could be used to distinguish occupied from unoccupied carriers. The read-out was entirely electrical so it could be miniaturized, enabling point-of-care detection. Taken together, this enabled quantitative biosensing via counting of individual occupied DNA origami carriers, which was demonstrated in physiological solutions and diluted human plasma.

First author, Dr. Mukhil Raveendran, a researcher at the University of Leeds, said, "One of the main advantages is the minimal sample needed. We are able to isolate individual molecules from small samples to identify specific illnesses. The process is very quick, and takes just minutes to provide results. The captured biomarkers are then read with nanopores and we can do this one molecule at a time. By coupling DNA origami and nanopores we are able to quantitatively detect disease biomarkers with single molecule sensitivity."

The DNA origami-nanopore biosensing platform was described in the September 1, 2020, online edition of the journal Nature Communications.

Related Links:
University of Leeds


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.